PWSA Blog

Letter to Community on FDA’s Extension of DCCR Review

Dear PWS Families,

We understand that hearing about the FDA’s extension of the review period for DCCR (diazoxide choline controlled release) may bring a mix of emotions, from hope to concern. Please know that this is a normal and expected part of the FDA’s thorough process, especially for a rare disease medication that has been granted pediatric priority review status.

The extension is often a sign of the FDA’s commitment to fully evaluating all aspects of the New Drug Application (NDA) to ensure the treatment’s safety and effectiveness for our loved ones. This step underscores the complexity of rare disease drug development, where careful consideration is essential to delivering the best possible outcomes.

PWSA | USA is here for our community every step of the way and we are inspired by your resilience and hope as we navigate this journey together. Rest assured, the dedication of researchers, advocates, and families like yours continues to propel progress forward. If you have questions, concerns, or simply need someone to talk to, please don’t hesitate to reach out to us. Together, we will continue advocating for meaningful progress and supporting one another through this journey.

Let’s continue to hold onto hope and stay united in our mission to improve the lives of those living with Prader-Willi syndrome.

Sincerely, 

PWSA | USA

Share this!

Scroll to top